Structure Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Structure Therapeutics Inc. - overview
Established
2016
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Founded in 2016 and based in California, US, Structure Therapeutics Inc. , formerly trading under the name ShouTi, Inc. , operates as a biotechnology company that develops medicines for patients with chronic diseases, including cardiovascular, metabolic, and pulmonary conditions. The company's CEO Dr.
Stevens has been involved in the discovery and development of several therapeutic molecules including Palnziq, which was developed at BioMarin Pharmaceutical and approved in 2018 to treat phenylketonuria. He also founded Receptos which developed Zeposia—a GPCR agonist targeting the S1PR1 receptor approved in 2020 for multiple sclerosis and 2021 for ulcerative colitis. In February 2023, Structure Therapeutics Inc. raised USD 161.
1 million in an IPO at USD 15 per share on the Nasdaq under the ticker symbol "GPCR". The company focuses on G-protein coupled receptors (GPCRs). Its platform enables the conversion of biologics and peptide therapeutics into orally available small molecule drugs with enhanced pharmaceutical properties, including improved bioavailability and stability. Using artificial intelligence, machine learning, and other techniques, the company designs small molecules intended to address validated targets of biologic drugs.
Current Investors
Qiming Venture Partners, F-Prime Capital, Hong Shan
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.structuretx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.